brain waves image

Output Catalog

ASAP is committed to accelerating the pace of discovery and informing a path to a cure for Parkinson’s disease through collaboration, research-enabling resources, and data sharing. We’ve created this catalog to showcase the research outputs and tools developed by ASAP-funded programs.

  results for ""
Sort
  • Output Type
  • Program
  • CRN Team Name
  • Theme

Parkinson’s Progression Markers Initiative: A Milestone-Based Strategy to Monitor PD Progression

Challenge: Identifying a meaningful progression metric for Parkinson’s disease (PD) that reflects heterogeneity remains a challenge. Objective: To assess the frequency and baseline predictors of progression to clinically relevant motor and…

Program: Parkinson's Progression Markers Initiative
View Article

Impact of the dopamine system on long-term cognitive impairment in Parkinson disease: an exploratory study

Background Little is known about the impact of the dopamine system on development of cognitive impairment (CI) in Parkinson disease (PD). Using data from a multi-site, international, prospective cohort study, authors explored the impact of dopamine…

Program: Parkinson's Progression Markers Initiative
View Article

Longitudinal Analysis of Multiple Neurotransmitter Metabolites in Cerebrospinal Fluid in Early Parkinson’s Disease

The aim of this study was quantification of multiple metabolites in CSF from PD versus healthy control subjects (HCs), including longitudinal analysis. Baseline levels of homovanillic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) were lower…

Program: Parkinson's Progression Markers Initiative
View Article

Biomarkers of neurodegeneration and glial activation validated in Alzheimer’s disease assessed in longitudinal cerebrospinal fluid samples of Parkinson’s disease

Several pathophysiological processes are involved in Parkinson’s disease (PD) and could inform in vivo biomarkers. We assessed an established biomarker panel, validated in Alzheimer’s Disease, in a PD cohort. Except for αSyn, the additional…

Program: Parkinson's Progression Markers Initiative
View Article

The longitudinal progression of autonomic dysfunction in Parkinson’s disease: a 7-year study

Autonomic dysfunction, including gastrointestinal, cardiovascular, and urinary dysfunction, is often present in early Parkinson’s Disease (PD). However, the knowledge of the longitudinal progression of these symptoms, and the connection…

Program: Parkinson's Progression Markers Initiative
View Article

Urinary bis(monacylglycerol) phosphate (BMP) levels are higher in LRRK2 and GBA1 variant carriers but do not predict disease progression in PPMI cohorts

We quantified concentrations of three isoforms of the endolysosomal lipid, bis(monoacylglycerol) phosphate (BMP) in urine of deeply phenotyped cohorts in the Parkinson’s Progression Markers Initiative: LRRK2 G2019S PD (N = 134) and…

Program: Parkinson's Progression Markers Initiative
View Article

Dopamine transporter imaging predicts clinically‐defined α‐synucleinopathy in REM sleep behavior disorder

Individuals with idiopathic rapid eye movement sleep behavior disorder (iRBD) are at high risk for a clinical diagnosis of an α‐synucleinopathy (aSN). They could serve as a key population for disease‐modifying trials. Abnormal dopamine…

Program: Parkinson's Progression Markers Initiative
View Article

High diagnostic performance of independent alpha-synuclein seed amplification assays for detection of early Parkinson’s disease

Alpha-synuclein seed amplification assays (αSyn-SAAs) are promising diagnostic tools for Parkinson’s disease (PD) and related synucleinopathies. They enable detection of seeding-competent alpha-synuclein aggregates in living patients and have…

Program: Parkinson's Progression Markers Initiative
View Article

Updated Percentiles for the University of Pennsylvania Smell Identification Test in Adults 50 Years of Age and Older

The University of Pennsylvania Smell Identification Test (UPSIT) is commonly used to assess olfaction and screen for early detection of disorders including Parkinson (PD) and Alzheimer disease. Our objective was to develop updated percentiles, based…

Program: Parkinson's Progression Markers Initiative
View Article

Assessment of heterogeneity and disease onset in the Parkinson’s Progression Markers Initiative (PPMI) cohort using the α-synuclein seed amplification assay: a cross-sectional study

Background Recent research demonstrates that α-synuclein seed amplification assays (αSyn-SAA) accurately differentiate Parkinson’s disease (PD) patients from healthy controls (HC). We used the well-characterized, multicenter Parkinson’s…

Program: Parkinson's Progression Markers Initiative
View Article